SCI-110 in the Treatment of Tourette Syndrome

Phase 2 Not yet recruiting 164 enrolled Neurothera Labs Inc.

RandomizedCrossoverQuadruple-blindTreatment

To evaluate the efficacy, safety and tolerability of the cannabinoid-based medication SCI-110 compared to placebo in subjects with Tourette syndrome.

Evaluation	Drug	Modality	Dose	Route
Subject	Dronabinol	Other / unclassified	2.5 mg	Oral
Subject	Dronabinol	Other / unclassified	5 mg	Oral
Subject	Dronabinol	Other / unclassified	10 mg	Oral
Subject	Dronabinol	Other / unclassified	20 mg	Oral
Subject	Palmidrol	Small molecule	400 mg	Oral
Subject	Palmidrol	Small molecule	800 mg	Oral